AST-201 / Aptamer Sci - LARVOL DELTA

Aptamer Sciences begins dosing first patient with liver cancer treatment phase 1 [Google translation] (BioTimes) - "Aptamer Science...announced on the 11th that it has started administering the first patient to the phase 1 clinical trial of its solid cancer treatment drug 'AST-201'."

Trial status • Hepatocellular Cancer

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Aptamer Sciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Hepatology • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Aptamer Science, 'Liver Cancer Treatment' Clinical Trial Enters Ultra-High-Speed [Google translation] (Medipana) - "Aptamer Science...announced on the 15th that it has completed the application and approval of the Institutional Review Board (IRB) of Bundang Cha Hospital, National Cancer Center, Samsung Seoul Hospital, and Severance Hospital for the domestic clinical trial of 'AST-201', an aptamer-drug conjugate (ApDC) solid tumor treatment."

New trial • Oncology • Solid Tumor

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients with GPC3-positive Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Aptamer Sciences, Inc.

Metastases • New P1 trial • Hepatocellular Cancer • Hepatology • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Aptamer Science, Solid Cancer Domestic Phase 1 Approval… Focus on Data Acquisition [Google translation] (Medipana) - "Aptamer Sciences has received approval for a domestic phase 1 clinical trial for its solid tumor treatment 'AST-201'. The plan is to focus on clinical data in order to promote domestic and international technology transfers...Aptamer Sciences received approval for the domestic phase 1 clinical trial plan (IND) for its aptamer-drug conjugate (ApDC) solid tumor treatment AST-201 from the Ministry of Food and Drug Safety on the same day. This is a clinical trial previously applied for with the Ministry of Food and Drug Safety in March...The trial will be conducted in a multi-center, open, dose escalation and expansion format to evaluate the tolerability, safety, and pharmacodynamic characteristics of AST-201 when administered to patients with advanced solid tumors that are GPC3 positive...It is planned to be conducted until November 25, 2027....The target number of subjects is up to 70, with up to 36 in Phase 1a, and Phase 1b will be decided after the completion of Phase 1a."

New P1 trial • Oncology • Solid Tumor

AST-201 (pUMVC3-hIGFBP2 N-terminus) demonstrates anti-tumor effect in an ovarian cancer mouse model (AACR 2024) - P1, P2 | "A study demonstrated that AST-201 (IGFBP2 cancer vaccine) showed an anti-tumor effect as mono treatment and would be potentially leading to a synergistic effect with a combination regimen of pembrolizumab. Phase 2 randomized-controlled study of AST-201 in ovarian cancer will be initiated under the MRCT strategy (CornerStone-004 study, NCT05794659)."

Preclinical • Oncology • Ovarian Cancer • Solid Tumor • CD4 • CD8 • IGFBP2